Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: J Thorac Oncol. 2023 Feb 24;18(7):907–921. doi: 10.1016/j.jtho.2023.02.016

Figure 2.

Figure 2.

Efficacy of sitravatinib and nivolumab in patients with nonsquamous non-small cell lung cancer previously treated with CPI. (A) Best overall response in patients with PCB from CPI (n = 89). (B) Duration of treatment in patients with PCB from CPI who responded to treatment (n = 15). One patient with confirmed PR (indicated with ‘Other’) was enrolled in a rollover study (NCT04887870). AE, adverse event; CPI, checkpoint inhibitor therapy; CR, complete response; GDH, global deterioration of health; PCB, prior clinical benefit; PD, progressive disease; PR, partial response; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; SD, stable disease.